Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: A multicenter single arm phase II trial (SAKK 15/08)

Clinical Lung Cancer

Volumn 14, Issue 1, 2013, Pages 34-39

  Früh, Martin ^a,k   Cathomas, Richard ^b   Siano, Marco ^a   Tscherry, Gregor ^c   Zippelius, Alfred ^d   Mamot, Christoph ^e   Erdmann, Andreas ^f   Krasniqi, Fatima ^d   Rauch, Daniel ^g   Simcock, Mathew ^h   Küttel, Erika ^h   Fustier, Pierre ^h,i   Pless, Miklos ^j  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

^c Spital Uster   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e CANTONAL HOSPITAL AARAU   (Switzerland)

^f Kantonsspital Baden   (Switzerland)

^g Hospital of Thun   (Switzerland)

^h SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

ⁱ CELGENE CORPORATION   (United States)

^j CANTONAL HOSPITAL WINTERTHUR   (Switzerland)

^k Kantonsspital Winterthur ^*  (Switzerland)

more..

Author keywords

Extensive stage small cell lung cancer; Phase II trial; Serotonin; Small cell; Vascular disrupting; Vascular disruptive agent

Indexed keywords

CARBOPLATIN; PACLITAXEL; VADIMEZAN;

ADULT; ALLERGIC REACTION; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BLADDER OBSTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; COUGHING; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EDEMA; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HOARSENESS; HUMAN; INFECTION; INSOMNIA; LUNG SMALL CELL CANCER; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PNEUMOTHORAX; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SEROTONIN SYNDROME; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; WEIGHT REDUCTION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CARBOPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME; XANTHONES;

EID: 84871596278     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2012.04.001     Document Type: Article

References (43)

1. R. Govindan, N. Page, D. Morgensztern Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database J Clin Oncol 24 2006 4539 4544
2. P.C. Hoffman, A.M. Mauer, E.E. Vokes Lung cancer [review] Lancet 355 2000 479 485 Erratum in: Lancet 2000; 355:1280
3. F. Blackhall, N. Thatcher Chemotherapy for advanced lung cancer Eur J Cancer 40 2004 2345 2348
4. M. Lucchi, A. Mussi, G. Fontanini Small cell lung carcinoma (SCLC): the angiogenic phenomenon Eur J Cardiothorac Surg 6 2002 1105 1110
5. J. Denekamp Vascular endothelium as the vulnerable element in tumours Acta Radiol Oncol 23 1984 217 225
6. L.J. Zwi, B.C. Baguley, J.B. Gavin Blood flow failure as a major determinant in the antitumor action of flavone acetic acid J Natl Cancer Inst 81 1989 1005 1013
7. V. Mahadevan, S.T. Malik, A. Meager Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown Cancer Res 50 1990 5537 5542
8. L.M. Ching, W.R. Joseph, K.E. Crosier Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488) Cancer Res 54 1994 870 872
9. B.C. Baguley, G. Cole, L.L. Thomsen Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5,6-dimethylxanthenone- 4-acetic acid Cancer Chemother Pharmacol 33 1993 77 81
10. L. Zhao, L.M. Ching, P. Kestell Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): increased tumor vascular permeability Int J Cancer 116 2005 322 326
11. P.N. Lara Jr, J.Y. Douillard, K. Nakagawa Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer J Clin Oncol 29 2011 2965 2971
12. B.J. Roth, D.H. Johnson, L.H. Einhorn Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group J Clin Oncol 10 1992 282 291
13. W.K. Evans, R. Feld, N. Murray Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer A multicenter, randomized clinical trial by the National Cancer Institute of Canada Ann Intern Med 107 1987 451 458
14. S. Baka, R. Califano, R. Ferraldeschi Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer Br J Cancer 99 2008 442 447
15. D.V. Skarlos, E. Samantas, P. Kosmidis Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer A Hellenic Co-operative Oncology Group study Ann Oncol 5 1994 601 607
16. M. Fukuoka, K. Furuse, N. Saijo Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer J Natl Cancer Inst 83 1991 855 861
17. P.E. Postmus, G. Scagliotti, H.J. Groen Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial Eur J Cancer 32A 1996 1498 1503
18. A. Ardizzoni, V.C. Tjan-Heijnen, P.E. Postmus Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923 J Clin Oncol 20 2002 3947 3955
19. G. Giaccone, O. Dalesio, G.J. McVie Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group J Clin Oncol 11 1993 1230 1240
20. W.K. de Jong, H.J. Groen, M.G. Koolen Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer Eur J Cancer 43 2007 2345 2350
21. S. Baka, S. Mullamitha, L. Ashcroft Randomized phase III study of carboplatin and paclitaxel versus vincristine, doxorubicin and cyclophosphamide chemotherapy in intermediate and poor prognosis small cell lung cancer: preliminary results J Clin Oncol 24 suppl 2006 7059
22. L.R. Kelland Targeting established tumor vasculature: a novel approach to cancer treatment Curr Cancer Ther Rev 1 2005 1 9
23. D.W. Siemann, E. Mercer, S. Lepler Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy Int J Cancer 99 2002 1 6
24. B.G. Siim, A.E. Lee, S. Shalal-Zwain Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) Cancer Chemother Pharmacol 51 2003 43 52
25. N.R. Foster, Y. Qi, Q. Shi Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials Cancer 117 2011 1262 1271
26. A. Horn, S.E. Dahlberg, A.B. Sandler Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501 J Clin Oncol 24 2009 6006 6011
27. M.B. Jameson, P.I. Thompson, B.C. Baguley Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent Br J Cancer 88 2003 1844 1850
28. B.C. Baguley, L. Zhuang, P. Kestell Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects Oncol Res 9 1997 55 60
29. P. Kestell, L. Zhao, M.B. Jameson Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents Clin Chim Acta 314 2001 159 166
30. G.J. Rustin, C. Bradley, S. Galbraith 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study Br J Cancer 88 2003 1160 1167
31. M.J. McKeage, P. Fong, M. Jeffery 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent Clin Cancer Res 12 2006 1776 1784
32. B.C. Baguley, D.W. Siemann Temporal aspects of the action of ASA404 (vadimezan; DMXAA) Expert Opin Investig Drugs 19 2010 1413 1425
33. A.M. Moore, L.H. Einhorn, D. Estes Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial Lung Cancer 52 2006 93 97
34. T.S. Mok, Y.L. Wu, S. Thongprasert Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
35. G.V. Scagliotti, P. Parikh, J. von Pawel Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 2008 3543 3551
36. M.A. Socinski, E.F. Smit, P. Lorigan Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer J Clin Oncol 27 2009 4787 4792
37. D.R. Spigel, F.A. Greco, J.D. Zubkus Phase II trial of irinotecan, carboplatin, and bevacizumab treatment of patients with extensive-stage small-cell lung cancer J Thorac Oncol 4 2009 1555 1560
38. D.R. Spigel, P.M. Townley, D.M. Waterhouse Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial J Clin Oncol 29 2011 2215 2222
39. N.E. Ready, A.Z. Dudek, H.H. Pang Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study J Clin Oncol 29 2011 4436 4441
40. J.M. Davies, N.S. Dhruva, C.M. Walko A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients Lung Cancer 71 2011 151 155
41. B.J. Schneider, S.M. Gadgeel, N. Ramnath Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer J Thorac Oncol 6 2011 1117 1120
42. J. Han, K.Y. Lim, H.Y. Kim Phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer J Clin Oncol 29 suppl 2011 abstract 7084
43. Z.T. Zhou, F.X. Zhou, Q. Wei Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer Cancer Chemother Pharmacol 68 2011 1027 1032